The Certified Clinical Research Associate designation is now formally recognized by TransCelerate Biopharma, Inc. as evidence of Good Clinical Practice training.
The Certified Clinical Research Associate (CCRA) designation is now formally recognized by TransCelerate Biopharma, Inc. (www.transceleratebiopharmainc.com) as evidence of Good Clinical Practice (GCP) training.
Clinical research professionals who hold a current CCRA designation may use that designation as evidence of GCP training while working at any of TransCelerate's 19 member companies, freeing them from any potential obligatory and/or redundant GCP training.
TransCelerate member companies include some of the world's largest pharmaceutical and biotechnology companies with research and development (R&D) operations, including Johnson & Johnson, AstraZeneca, Pfizer, Roche, GlaxoSmithKline, and more. TransCelerate launched in 2012 "to advance innovation in R&D, identify and solve common R&D challenges, and further improve patient safety."
"The CCRA designation shows both my employer and the sites I monitor that I have taken the extra step to be a professional," says Kathryn Kimmel, CCRA, CCRC, Senior Clinical Research Associate at PAREXEL International. "The CCRA designation states I have not only GCP training, but know International Conference on Harmonization and all standards that are needed for good clinical research to be performed at the site level and within my company. It establishes me as someone who has demonstrated the ability to apply this knowledge."
Recognition of the CCRA designation follows TransCelerate's January 2014 recognition of the Certified Clinical Research Coordinator (CCRC) and Certified Physician Investigator (CPI) designations as evidence of GCP training. In February 2014, TransCelerate also recognized ACRP GCP training courses as evidence of required GCP training.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.